Increased extracellular DA and normal evoked DA release in the rat striatum after a partial lesion of the substantia nigra

Brain Research

Volumn 893, Issue 1-2, 2001, Pages 178-185

  Dentresangle, Christine ^a   Le Cavorsin, Marion ^a   Savasta, Marc ^b   Leviel, Vincent ^a,c  

^a CNRS   (France)

^b INSERM   (France)

^c PRECM   (France)

Author keywords

Dopamine release; Dopamine uptake; Parkinson's disease; Substantia nigra lesion

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; ELECTROSTIMULATION; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; AUTORADIOGRAPHY; CARRIER PROTEINS; CAUDATE NUCLEUS; CELL COUNT; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ELECTRIC STIMULATION; ELECTRODES, IMPLANTED; EXTRACELLULAR SPACE; HOMOVANILLIC ACID; MALE; MEDIAL FOREBRAIN BUNDLE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; OXIDOPAMINE; PUTAMEN; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 0035793996     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)03311-4     Document Type: Article

References (54)

1. Estimation of nuclear population from microtome sections
2. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in the rat
3. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: Implications for behavioral recovery from brain injury
4. Preservation of dopamine release in the denervated striatum
5. Ontogeny of tyrosine hydroxylase levels in the neuropil close to locus coeruleus
6. Cellular quantification of tyrosine hydroxylase in the rat brain by immunoautoradiography
7. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulation of dopaminergic neurons of the rat mesencephalon
8. Long-term induction of tyrosine hydroxylase expression: Compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain
9. Alterations in consummatory behavior following intraciternal injection of 6-hydroxydopamine
10. Increased neostriatal tyrosine hydroxylation during stress: Role of extracellular dopamine and excitatory amino acids
11. Studies of the in vivo catabolism of exogenous dopamine as infused through a push-pull cannula implanted in the rat caudate nucleus
12. Time-course of changes in striatal levels of DA uptake sites, DA D2 receptor and preproenkephalin mRNAs after nigrostriatal dopaminergic denervation in the rat
13. DA uptake sites, D1 and D2 receptors, D2 and preproenkephalin mRNAs and Fos immunoreactivity in rat striatal subregions after partial dopaminergic degeneration
14. Opposite presynaptic regulations by glutamate through NMDA receptors of dopamine synthesis and release in rat striatal synaptosomes
15. Pharmacological characterization of dopamine overflow in the striatum of the normal and MPTP-treated common marmoset, studied in vivo using fast cyclic voltammetry, nomifensine and sulpiride
16. Behavioral and neurochemical recovery from partial 6-hydroxydopamine lesions of the substantia nigra is blocked by daily treatment with glutamate receptor antagonists MK-801 and CPP
17. Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals
18. In vivo electrochemical studies of dopamine overflow and clearance in the striatum of normal and MPTP-treated rhesus monkeys
19. Electrochemical treatment of pyrolitic carbon fiber electrodes
20. In vivo monitoring of dopamine release in the rat brain with differential normal pulse voltammetry
21. Effects of dopamine agonists and antagonists on feeding in intact and 6-hydroxydopamine treated rats
22. Partial lesion of the dopamine nigrostriatal system in rat brain: Biochemical characterization
23. Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs
24. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum
25. The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons
26. Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson's disease
27. Phorbolesters alter functions of the expressed dopamine transporter
28. Direct observation of dopamine compartmentation in striatal nerve terminal by 'in vivo' measurement of the specific activity of released dopamine
29. Specifically evoked release of newly synthesized or stored dopamine by different treatments
30. The reverse transport of DA, what physiological significance
31. 3H]GBR12935 binding to dopamine uptake sites: Subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy
32. Comparison of the eating in response to hypothermic and glucoprivic challenges after nigral 6-hydroxydopamine and lateral hypothalamic electrolytic lesions in rats
33. Somatosensory inattention after dopamine depleting intracerebral 6-OHDA injections: Spontaneous recovery and pharmacological control
34. Effects of D2 antagonists on frequency dependent stimulated dopamine overflow in nucleus accumbens and caudate putamen
35. Autoradiographic localization of dopamine uptake sites in the rat brain with 3H-GBR 12935
36. Direct in vivo comparison of two mechanisms releasing dopamine in the rat striatum
37. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: A microdialysis study in freely moving rats
38. Biotransformation of L-Dopa in striatum and substrantia nigra of rats with a unilateral, nigrostriatal lesion: A microdialysis study
39. Overflow of endogenous dopamine and 3-4 dihydroxyphenylacetic acid from tissues of the rat brain, elicited by electrical stimulation, depolarization by potassium and activation of carrier-mediated release
40. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage
41. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: Evidence for compensatory hyperactivity of residual terminals
42. Uptake of dopamine released by impulse flow in the rat mesolimbic and striatal systems in vivo
43. Changes in the retention and metabolism of 3H-L-norepinephrine in rat brain in vivo after 6-hydroxydopamine pretreatment
44. Restoration of dopamine overflow and clearance from the 6-hydroxydopamine lesioned rat striatum reinnervated by fetal mesencephalic grafts
45. Regulation of dopamine uptake in rat striatal tissue by NMDA receptors as measured using rotating disk electrode voltammetry
46. A quantitative comparison on the effects of benztropine, cocaine and nomifensine on electrically evoked dopamine overflow and rate of re-uptake in the caudate putamen and nucleus accumbens in the rat brain slice
47. Glutamate receptors in striatum and substantia nigra: Effects of medial forebrain bundle lesions
48. In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC
49. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage
50. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions
51. Compensatory response to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism
52. Compensatory changes after lesions of central dopaminergic neurons: Some clinical and basis implications